Advances in the prevention of Alzheimer's disease and dementia

Definitions and diagnostic criteria for all medical conditions are regularly subjected to reviews and revisions as knowledge advances. In the field of Alzheimer's disease (AD) research, it has taken almost three decades for diagnostic nomenclature to undergo major re‐examination. The shift towards presymptomatic and pre‐dementia stages of AD has brought prevention and treatment trials much closer to each other than before.

[1]  Wendy J Mack,et al.  Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review , 2011, Alzheimer's Research & Therapy.

[2]  S. Worley.  After disappointments, Alzheimer's researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say. , 2014, P & T : a peer-reviewed journal for formulary management.

[3]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[4]  John W. Williams,et al.  Preventing Alzheimer's disease and cognitive decline. , 2010, Evidence report/technology assessment.

[5]  D A Bennett,et al.  Relation of cognitive activity to risk of developing Alzheimer disease , 2007, Neurology.

[6]  Arto Mannermaa,et al.  Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease , 2002, Annals of Internal Medicine.

[7]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[8]  E. Ross,et al.  Philosophy of Science Association , 2022 .

[9]  R. Green,et al.  Extended results of the Alzheimer’s disease anti-inflammatory prevention trial , 2011, Alzheimer's & Dementia.

[10]  Draft Guidance.  Guidance for Industry Alzheimer ’ s Disease : Developing Drugs for the Treatment of Early Stage Disease DRAFT GUIDANCE , 2013 .

[11]  Perminder S. Sachdev,et al.  Dementia in the oldest old , 2013, Nature Reviews Neurology.

[12]  P. Kamphuis,et al.  Nutritional approaches in the risk reduction and management of Alzheimer's disease. , 2013, Nutrition.

[13]  B. Schmand,et al.  Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. , 2012, Journal of Alzheimer's disease : JAD.

[14]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[15]  Hui-Xin Wang,et al.  Brain reserve hypothesis in dementia. , 2007, Journal of Alzheimer's disease : JAD.

[16]  B. Winblad,et al.  Risk and protective effects of the APOE gene towards Alzheimer’s disease in the Kungsholmen project: variation by age and sex , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[18]  R. Green,et al.  Risk of dementia among white and African American relatives of patients with Alzheimer disease. , 2002, JAMA.

[19]  C. V. von Arnim,et al.  More than the sum of its parts? Nutrition in Alzheimer's disease. , 2010, Nutrition.

[20]  J. Schneider,et al.  Loneliness and risk of Alzheimer disease. , 2007, Archives of general psychiatry.

[21]  H. Seo,et al.  Effects of Selenium Supplements on Cancer Prevention: Meta-analysis of Randomized Controlled Trials , 2011, Nutrition and cancer.

[22]  Bess Dawson-Hughes,et al.  Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.

[23]  W. Markesbery,et al.  Recent Clinical-Pathologic Research on the Causes of Dementia in Late Life: Update From the Honolulu-Asia Aging Study , 2005, Journal of geriatric psychiatry and neurology.

[24]  F. Panza,et al.  Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease , 2009, Ageing Research Reviews.

[25]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[26]  C. Reitz.  Dyslipidemia and the Risk of Alzheimer’s Disease , 2013, Current Atherosclerosis Reports.

[27]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[28]  B. Winblad,et al.  Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden , 2013, Neurology.

[29]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[30]  A Alioum,et al.  Modelling age-specific risk: application to dementia. , 1998, Statistics in medicine.

[31]  Gretchen A. Stevens,et al.  National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants , 2011, The Lancet.

[32]  A. Roses,et al.  A pharmacogenetics-supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease , 2013, Alzheimer's & Dementia.

[33]  G. Schellenberg,et al.  Creating a transatlantic research enterprise for preventing Alzheimer's disease , 2009, Alzheimer's & Dementia.

[34]  M. Weiner,et al.  Featured Articles Developing a global strategy to prevent Alzheimer's disease: Leon , 2011 .

[35]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[36]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[37]  J. Crowley,et al.  A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. , 2012, The journal of nutrition, health & aging.

[38]  A. Hofman,et al.  Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. , 1998, Archives of neurology.

[39]  A. Börjesson-Hanson,et al.  Prevalence of cardiovascular disorders and risk factors in two 75-year-old birth cohorts examined in 1976–1977 and 2005–2006 , 2013, Aging Clinical and Experimental Research.

[40]  B. Winblad,et al.  Late‐Life Body Mass Index and Dementia Incidence: Nine‐Year Follow‐Up Data from the Kungsholmen Project , 2008, Journal of the American Geriatrics Society.

[41]  J. Morris,et al.  The Dominantly Inherited Alzheimer's Network , 2010, Alzheimer's & Dementia.

[42]  Qualification opinion of Alzheimer ’ s disease novel methodologies / biomarkers for PET amyloid imaging ( positive / negative ) as a biomarker for enrichment , for use in regulatory clinical trials in predementia Alzheimer ’ s disease , 2012 .

[43]  E. Richard,et al.  Prevention of Dementia by Intensive Vascular Care (PreDIVA): A Cluster-randomized Trial in Progress , 2009, Alzheimer disease and associated disorders.

[44]  J. Schneider,et al.  Neural reserve, neuronal density in the locus ceruleus, and cognitive decline , 2013, Neurology.

[45]  V. Henderson.  Alzheimer's disease: Review of hormone therapy trials and implications for treatment and prevention after menopause , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  Hilkka Soininen,et al.  Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study , 2006, The Lancet Neurology.

[47]  M. Postma,et al.  Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients , 2012, Drugs.

[48]  G. Strobel.  Alzheimer's prevention initiative. , 2010, Journal of Alzheimer's disease : JAD.

[49]  Jen‐Hau Chen,et al.  Risk factors for dementia. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.

[50]  Carol Brayne,et al.  Education, the brain and dementia: neuroprotection or compensation? , 2010, Brain : a journal of neurology.

[51]  C. Mulrow,et al.  Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials , 2000, BMJ : British Medical Journal.

[52]  C. Brayne,et al.  Making Alzheimer's and dementia research fit for populations , 2012, The Lancet.

[53]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[54]  David A Bennett,et al.  Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age. , 2012, Archives of general psychiatry.

[55]  Z. Khachaturian.  Alzheimer's & Dementia: The Journal of the Alzheimer's Association , 2008, Alzheimer's & Dementia.

[56]  J. Schneider,et al.  The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study , 2006, The Lancet Neurology.

[57]  Kristine Yaffe,et al.  Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts. , 2014, Journal of Alzheimer's disease : JAD.

[58]  Bruno Vellas,et al.  Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force , 2013, Alzheimer's & Dementia.

[59]  P. Galan,et al.  Beta‐carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials , 2010, International Journal of Cancer.

[60]  Randall J Bateman,et al.  Dominantly Inherited Alzheimer Network: facilitating research and clinical trials , 2013, Alzheimer's Research & Therapy.

[61]  L. Schneider,et al.  Report of the task force on designing clinical trials in early (predementia) AD , 2010, Neurology.

[62]  A. Smith,et al.  Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease , 1995, Neuroscience.

[63]  Kewei Chen,et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.

[64]  B. Winblad,et al.  Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study , 2004, BMJ : British Medical Journal.

[65]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[66]  J. Shaw,et al.  IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. , 2011, Diabetes research and clinical practice.

[67]  R. Lucas,et al.  Association or causation: evaluating links between "environment and disease". , 2005, Bulletin of the World Health Organization.

[68]  E. Richard,et al.  Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review , 2010, Vascular health and risk management.

[69]  Hilkka Soininen,et al.  Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.

[70]  Carol Brayne,et al.  Age, neuropathology, and dementia. , 2009, The New England journal of medicine.

[71]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[72]  S. Haneuse,et al.  Pathological correlates of dementia in a longitudinal, population‐based sample of aging , 2007, Annals of neurology.

[73]  J. Dartigues,et al.  Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): A new approach to the prevention of Alzheimer's disease , 2009, Alzheimer's & Dementia.

[74]  David Craig,et al.  Risk factors for dementia. , 2001 .

[75]  L. Fratiglioni,et al.  Dementia prevention: current epidemiological evidence and future perspective , 2012, Alzheimer's Research & Therapy.

[76]  P. Passmore,et al.  Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. , 2009, The Cochrane database of systematic reviews.

[77]  R. Wilson,et al.  Relation of neuropathology to cognition in persons without cognitive impairment , 2012, Annals of neurology.

[78]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[79]  K. Zahs,et al.  ‘Too much good news’ – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? , 2010, Trends in Neurosciences.

[80]  Kristine Yaffe,et al.  Potential for primary prevention of Alzheimer's disease: an analysis of population-based data , 2014, The Lancet Neurology.

[81]  H. Walach,et al.  Towards Primary Prevention of Alzheimers Disease , 2012 .

[82]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[83]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[84]  Kewei Chen,et al.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.

[85]  M. M. Mielke,et al.  High total cholesterol levels in late life associated with a reduced risk of dementia , 2005, Neurology.

[86]  S. Henderson.  Epidemiology of dementia. , 1998, Annales de medecine interne.

[87]  Asher Mullard,et al.  Multicompany trials adapt to disciplines beyond cancer , 2014, Nature Medicine.

[88]  S. Black,et al.  Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[89]  S. Ukraintseva,et al.  Declining prevalence of dementia in the U.S. elderly population. , 2005, Advances in gerontology = Uspekhi gerontologii.

[90]  S. Leurgans,et al.  Cognitive reserve, presynaptic proteins and dementia in the elderly , 2012, Translational Psychiatry.

[91]  A. Bachoud-Lévi,et al.  Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis , 2013, Journal of hypertension.

[92]  L. Fratiglioni,et al.  Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal , 2011, The Lancet Neurology.

[93]  Y. Stern.  Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[94]  Ronald C Petersen,et al.  Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. , 2011, Mayo Clinic proceedings.

[95]  H. Soininen,et al.  Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. , 2009, Journal of Alzheimer's disease : JAD.

[96]  Geert Jan Biessels,et al.  Midlife risk score for the prediction of dementia four decades later , 2014, Alzheimer's & Dementia.

[97]  C. Bell,et al.  Risk factors and preventive interventions for Alzheimer disease: state of the science. , 2011, Archives of neurology.

[98]  G. Jicha,et al.  Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease , 2010, Clinical interventions in aging.

[99]  R. Green,et al.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial , 2007, Neurology.

[100]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[101]  A. LaCroix,et al.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data , 2013, The Lancet.

[102]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[103]  R. Westendorp,et al.  The Alzheimer myth and biomarker research in dementia. , 2012, Journal of Alzheimer's disease : JAD.

[104]  Susan M Resnick,et al.  Longitudinal patterns of β-amyloid deposition in nondemented older adults. , 2011, Archives of neurology.

[105]  P. Passmore,et al.  Statins for the prevention of dementia. , 2009, The Cochrane database of systematic reviews.

[106]  R. Luff,et al.  Immunohistochemical localization of glutathione S-transferase in preneoplastic and neoplastic lesions of the human uterine cervix. , 1991, Acta cytologica.

[107]  G. Logroscino,et al.  Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective? , 2012, International journal of geriatric psychiatry.

[108]  David A. Snowdon,et al.  Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study , 2005, Neurobiology of Aging.

[109]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[110]  C. Berr,et al.  Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors , 2010, BMJ : British Medical Journal.

[111]  L. Marsh,et al.  Treatment of early Parkinson's disease , 2000, BMJ : British Medical Journal.

[112]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[113]  Alan D. Lopez,et al.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.

[114]  Stirling Bryan,et al.  Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment , 2010, BMC neurology.

[115]  H. Soininen,et al.  Future directions in Alzheimer's disease from risk factors to prevention. , 2014, Biochemical pharmacology.

[116]  H. Soininen,et al.  Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. , 2012, Journal of Alzheimer's disease : JAD.

[117]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[118]  I. Skoog,et al.  Blood Pressure Trajectories From Midlife to Late Life in Relation to Dementia in Women Followed for 37 Years , 2012, Hypertension.

[119]  Simon Lovestone,et al.  Alzheimer's disease – do tauists and baptists finally shake hands? , 2002, Trends in Neurosciences.

[120]  P. Zimmet,et al.  Epidemiology: Global burden of disease—where does diabetes mellitus fit in? , 2013, Nature Reviews Endocrinology.

[121]  N. Sattar,et al.  Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. , 2012, Archives of internal medicine.

[122]  L. Fratiglioni,et al.  Methodological challenges in designing dementia prevention trials — The European Dementia Prevention Initiative (EDPI) , 2012, Journal of the Neurological Sciences.

[123]  J. Bond,et al.  A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II , 2013, The Lancet.

[124]  R. Petersen,et al.  Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease , 2013, Alzheimer's & Dementia.

[125]  L. Thal,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[126]  M. Mancuso,et al.  Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease. , 2012, Current neurovascular research.

[127]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[128]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[129]  A. B. Hill,et al.  "The Environment and Disease: Association or Causation?" (1965), by Austin Bradford Hill , 2017 .

[130]  J. Karlawish,et al.  Trends in the prevalence and mortality of cognitive impairment in the United States: Is there evidence of a compression of cognitive morbidity? , 2008, Alzheimer's & Dementia.

[131]  T. A. D. A. P. T. Group.  Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) , 2013, Alzheimer's & Dementia.

[132]  S. Gauthier,et al.  Early-Onset Familial Alzheimer's Disease (EOFAD) , 2012, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[133]  The European Dementia Prevention Initiative , 2013, The Lancet Neurology.

[134]  B. Vellas,et al.  Dementia prevention: methodological explanations for inconsistent results. , 2008, Epidemiologic reviews.

[135]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[136]  M. Kivipelto,et al.  Prevention of Alzheimer’s Disease: Intervention Studies , 2013 .

[137]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[138]  Lewis H Kuller,et al.  Ginkgo biloba for prevention of dementia: a randomized controlled trial. , 2008, JAMA.

[139]  C. Bulpitt,et al.  Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.

[140]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[141]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[142]  David A Bennett,et al.  Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. , 2007, Archives of general psychiatry.

[143]  Veikko Salomaa,et al.  Thirty-five-year trends in cardiovascular risk factors in Finland. , 2010, International journal of epidemiology.

[144]  B. Dubois,et al.  Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial , 2012, The Lancet Neurology.

[145]  Cognitive reserve, cortical plasticity and resistance to Alzheimer's disease , 2012, Alzheimer's Research & Therapy.

[146]  W. Kukull,et al.  Epidemiology of dementia: concepts and overview. , 2000, Neurologic clinics.

[147]  D. Drachman.  Commentary on “A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium.” Prevention of dementia: Roadmap or maintenance manual? , 2008, Alzheimer's & Dementia.

[148]  John Bond,et al.  The worldwide economic impact of dementia 2010 , 2013, Alzheimer's & Dementia.

[149]  Richard N Kocsis,et al.  Book Review: Diagnostic and Statistical Manual of Mental Disorders: Fifth Edition (DSM-5) , 2013 .

[150]  M. Weiner,et al.  Developing a global strategy to prevent Alzheimer’s disease: Leon Thal Symposium 2010 , 2011, Alzheimer's & Dementia.

[151]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[152]  R. Frikke-Schmidt,et al.  APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease , 2001, Neurology.

[153]  J. Dartigues,et al.  Recruitment strategies for preventive trials. The MAPT study (Multidomain Alzheimer Preventive Trial) , 2012, The journal of nutrition, health & aging.

[154]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[155]  Keith A. Johnson,et al.  Preclinical Alzheimer disease—the challenges ahead , 2013, Nature Reviews Neurology.

[156]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[157]  L. Fratiglioni,et al.  Preventing Alzheimer Disease and Cognitive Decline , 2011, Annals of Internal Medicine.

[158]  A. Zonderman,et al.  Neuronal Hypertrophy in Asymptomatic Alzheimer Disease , 2008, Journal of neuropathology and experimental neurology.

[159]  P. Mecocci,et al.  Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.

[160]  H. Soininen,et al.  Recruitment and Baseline Characteristics of Participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)—A Randomized Controlled Lifestyle Trial † , 2014, International journal of environmental research and public health.

[161]  G. Miller.  Alzheimer's research. Stopping Alzheimer's before it starts. , 2012, Science.

[162]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[163]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[164]  Donald Silberberg,et al.  National Institutes of Health State-of-the-Science Conference Statement: Preventing Alzheimer Disease* and Cognitive Decline , 2010, Annals of Internal Medicine.

[165]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[166]  H. Soininen,et al.  The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress , 2013, Alzheimer's & Dementia.

[167]  Sm,et al.  Risk Factors for , 2002 .

[168]  Sang Min Park,et al.  Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials , 2013, BMJ.

[169]  M. Norton,et al.  Common psychosocial stressors in middle-aged women related to longstanding distress and increased risk of Alzheimer's disease: a 38-year longitudinal population study , 2013, BMJ Open.

[170]  M. Reed,et al.  Glutamate dysregulation in tau P301L mice , 2013, Alzheimer's & Dementia.

[171]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.